Jaanam Lalchandani

Jaanam Lalchandani

Auto-generated profile, based on publicly available information

Jaanam Lalchandani

Fundación para la Investigación Biomédica Hospital Infantil Universitario Niño Jesús (FIBHNJS) Oncohematology Department Madrid 28009

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2024 in Antiviral Research
Verified
Journal Article
Open access
FPFrancisco Mancebo Pascual
Francisco Mancebo Pascual
MNMarcos Nuévalos
Marcos Nuévalos
JLJaanam Lalchandani
Jaanam Lalchandani
Antonio J. Martin-GalianoAntonio J. Martin-Galiano
Antonio J. Martin-Galiano
MFMario Fernández-Ruiz
Mario Fernández-Ruiz
Pilar Pérez RomeroPilar Pérez Romero
Pilar Pérez Romero
Due to the severity of CMV infection in immunocompromised individuals the development of a vaccine has been declared a priority. However, despite the efforts made there is no yet a vaccine available for clinical use. We designed an approach to identify new CMV antigens able to inducing a broad immune response that could be used in future vaccine formulations. We have used serum samples from 28 kidney transplant recipients, with a previously acquired CMV-specific immune response to identify viral proteins that were recognized by the antibodies present in the patient serum samples by Western blot. A band of approximately 45 kDa, identified as UL44, was detected by most serum samples. UL44 immunogenicity was tested in BALB/c mice that received three doses of the UL44-pcDNA DNA vaccine. UL44 elicited both, a strong antibody response and CMV-specific cellular response. Using bioinformatic analysis we demonstrated that UL44 is a highly conserved protein and contains epitopes that are able to activate CD8 lymphocytes of the most common HLA alleles in the world population. We constructed a UL44 ORF deletion mutant virus that produced no viral progeny, suggesting that UL44 is an essential viral protein. In addition, other authors have demonstrated that UL44 is one of the most abundant viral proteins after infection and have suggested an essential role of UL44 in viral replication. Altogether, our data suggests that UL44 is a potent antigen, and favored by its abundance, it may be a good candidate to include in a vaccine formulation.

7 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ACAna Casado-García
Ana Casado-García
GGGonzalo García-Aguilera
Gonzalo García-Aguilera
JPJulio Pozo
Julio Pozo
NONinad Oak
Ninad Oak
SBSusana Barrena
Susana Barrena
ISIsidro Sanchez-Garcia
Isidro Sanchez-Garcia
In children developing B-cell acute lymphoblastic leukemia (B-ALL), an immune evasion event takes place where otherwise “silent” preleukemic cells undergo a malignant transformation while escaping immune control, often by unknown mechanisms. Here, we identify the upregulation of PD-1 expression in preleukemic cells, triggered by Pax5 inactivation in mice and correlating with the time of conversion to leukemia, as a novel marker that favors leukemia evasion. This increase in PD-1 expression is apparent across diverse molecular B-ALL subtypes, both in mice and humans. PD-1 is not required for B-cell leukemogenesis but in the absence of PD-1, tumor cells express NK cell inhibitory receptors highlighting the necessity for leukemic cells to evade the host's NK immune response in order to exit the bone marrow. PD-1 expression reduces natural anti-tumor immune responses, but it sensitizes leukemic cells to immune checkpoint blockade strategies in mice and humans. PD-1 targeting confers clinical benefit by restoring NK-mediated tumor cell killing in vitro and eliminating tumor cells in vivo in mice engrafted with B-ALL. These results identify PD-1 as a new therapeutic target against leukemic progression, providing new opportunities for the treatment and possibly also the prevention of childhood B-ALL.

5 July 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
MPMarta Portasany-Rodríguez
Marta Portasany-Rodríguez
GSGonzalo Soria-Alcaide
Gonzalo Soria-Alcaide
ESElena G. Sánchez
Elena G. Sánchez
MIMaría Ivanova
María Ivanova
AGAna Gómez
Ana Gómez
RGReyes Giménez
Reyes Giménez
Short Structured Summary: PULPO v1.0 is a novel, fully automated pipeline designed for the preprocess and extraction of mutational signatures from raw Optical Genome Mapping (OGM) data. Built using Snakemake and executed within an isolated, Conda-managed environment, PULPO transforms complex cytogenetic alterations, captured at ultra-high resolution, into Catalogue of somatic mutations in Cancer (COSMIC)-based mutational signatures. This innovative approach not only enables researchers to work directly from raw OGM inputs but also streamlines the traditionally complex process of signature extraction, making advanced oncogenomic analyses accessible to users with varying levels of bioinformatics expertise. By facilitating the integration of comprehensive structural variants (SVs) and copy number variants (CNVs) data with established signature catalogs, PULPO paves the way for improved diagnostic accuracy and personalized therapeutic strategies. Availability and Implementation: The pipeline is open source and freely available under the MIT License at https://github.com/OncologyHNJ/PULPO .

12 November 2025 in Hematology Reports
Verified
Journal Article
Open access
PDF file
ACAna Casado-García
Ana Casado-García
GGGonzalo García-Aguilera
Gonzalo García-Aguilera
JPJulio Pozo
Julio Pozo
NONinad Oak
Ninad Oak
SBSusana Barrena
Susana Barrena
ISIsidro Sanchez-Garcia
Isidro Sanchez-Garcia
Background/Objectives: In children developing B-cell acute lymphoblastic leukemia (B-ALL), an immune evasion event takes place where otherwise “silent” preleukemic cells undergo a malignant transformation while escaping immune control, often through unknown mechanisms. Methods and Results: Here, we identify the upregulation of PD-1 expression in preleukemic cells, triggered by Pax5 inactivation in mice and correlating with the time of conversion to leukemia, as a novel marker that favors leukemia evasion. This increase in PD-1 expression is apparent across diverse molecular B-ALL subtypes, both in mice and humans. PD-1 is not required for B-cell leukemogenesis, but, in the absence of PD-1, tumor cells express NK cell inhibitory receptors, highlighting the necessity for leukemic cells to evade the host’s NK immune response in order to exit the bone marrow. PD-1 expression reduces natural antitumor immune responses, but it sensitizes leukemic cells to immune checkpoint blockade strategies in mice and humans. PD-1 targeting confers clinical benefits by restoring NK-mediated tumor cell killing in vitro and eliminating tumor cells in vivo in mice engrafted with B-ALL. Conclusions: These results identify PD-1 as a new therapeutic target against leukemic progression, providing new opportunities for the treatment and possibly also the prevention of childhood B-ALL.

10 March 2026 in Bioinformatics
Verified
Journal Article
Open access
PDF file
MPMarta Portasany-Rodríguez
Marta Portasany-Rodríguez
GSGonzalo Soria-Alcaide
Gonzalo Soria-Alcaide
ESElena G Sánchez
Elena G Sánchez
MIMariya Ivanova
Mariya Ivanova
AGAna Gómez
Ana Gómez
JMJorge García Martínez
Jorge García Martínez
PULPO v1.0 is a novel, fully automated pipeline designed for the preprocess and extraction of mutational signatures from raw Optical Genome Mapping (OGM) data. Built using Snakemake and executed within an isolated, Conda-managed environment, PULPO transforms complex cytogenetic alterations, captured at ultra-high resolution, into Catalogue of somatic mutations in cancer mutational signatures (COSMIC). This innovative approach not only enables researchers to work directly from raw OGM inputs but also streamlines the traditionally complex process of signature extraction, making advanced oncogenomic analyses accessible to users with varying levels of bioinformatics expertise. By facilitating the integration of comprehensive structural variants (SVs) and copy number variants (CNVs) data with established signature catalogues, PULPO paves the way for improved diagnostic accuracy and personalized therapeutic strategies. The pipeline is open source and freely available under the MIT License at https://github.com/OncologyHNJ/PULPO-v.1.0 and DOI in Zenodo: https://zenodo.org/records/17749097. Supplementary data are available at Bioinformatics online.